Pharmacodynamics: Mechanisms of Drug Action

This comprehensive guide goes entirely into Pharmacodynamics. It leaves no stone unturned, elaborating on every principle, mechanism, receptor type, and clinical correlation discussed. You will thoroughly understand how drugs exert their effects from the macroscopic organ level down to the microscopic cellular and genetic levels.

---

What is Pharmacodynamics?

If pharmacokinetics is what the body does to the drug, Pharmacodynamics asks the fundamental question: What does the drug do to the body when it enters?

---

Core Principles of Drug Action

Before understanding how drugs work, we must understand what they are capable of doing. The most critical rule in pharmacology is:

Drugs act through five basic types of action:

1. Stimulation

This is the selective enhancement of the level of activity of specialized cells. The drug kicks a natural process into a higher gear.

• Example 1: Adrenaline stimulates the heart, increasing both the heart rate and the force of contraction.
• Example 2: Pilocarpine stimulates the salivary glands, causing an increase in saliva production (useful in treating dry mouth).
• Warning Note: Excessive stimulation can exhaust the system and lead to depression. For example, a high dose of picrotoxin overstimulates the central nervous system (CNS), causing violent convulsions, which eventually tires the brain out, leading to coma and respiratory depression.

2. Depression

This is the selective diminution (reduction) of the activity of specialized cells. The drug slows a process down.

• Example 1: Barbiturates depress the Central Nervous System, causing sedation and sleep.
• Example 2: Quinidine depresses the heart's electrical excitability, used to treat cardiac arrhythmias.
• Example 3: Omeprazole depresses gastric acid secretion in the stomach to heal ulcers.
• Organ Specificity: A drug can stimulate one organ while depressing another. Acetylcholine stimulates the smooth muscles of the intestines (causing cramping/movement) but strongly depresses the SA node in the heart (slowing the heart rate).

3. Irritation

Unlike stimulation or depression, irritation is a nonselective, often noxious (harmful) effect. It is particularly applied to less specialized cells, such as the epithelium (skin/mucosa) and connective tissue.

• Mild irritation: Can be used therapeutically (e.g., counterirritants in muscle rubs to increase local blood flow).
• Strong irritation: Results in severe tissue damage, including inflammation, corrosion, cellular necrosis (death), and permanent morphological damage.

4. Replacement

This involves the administration of natural metabolites, hormones, or their synthetic congeners (chemical cousins) to treat specific deficiency states.

• Example 1: Levodopa is given in Parkinsonism to replace the missing neurotransmitter dopamine.
• Example 2: Insulin is given to patients with Diabetes Mellitus to replace the hormone their pancreas no longer makes.
• Example 3: Iron supplements are given to replace depleted stores in anemia.

5. Cytotoxic Action

This is a selective toxic action aimed at invading parasites, bacteria, or rogue cancer cells, successfully attenuating (weakening/killing) them without significantly affecting the host's healthy cells.

• This action is heavily utilized for the cure or palliation (relief of symptoms) of infections and neoplasms (tumors).
• Examples: Penicillin (kills bacteria), Chloroquine (kills malaria parasites), Zidovudine (antiviral for HIV), and Cyclophosphamide (anti-cancer chemotherapy).

---

3. Mechanisms of Drug Action

How do drugs actually achieve these effects? We divide the mechanisms into two major categories: Non-Receptor (Physical/Chemical) Mechanisms and Target Biomolecule Interactions.

A. Non-Receptor Mechanisms (Physical & Chemical Properties)

Only a small handful of drugs act simply by virtue of their raw physical bulk or chemical reactivity, without ever needing to bind to a cellular target. These include:

• Physical mass: Bulk laxatives like ispaghula (psyllium) simply absorb water and physically swell up in the gut to promote bowel movements.
• Absorption of UV rays: Para-aminobenzoic acid (PABA) in sunscreens acts as a physical shield against the sun.
• Adsorptive property: Activated charcoal acts like a chemical sponge, adsorbing toxins in the stomach during an overdose.
• Osmotic activity: Mannitol and magnesium sulfate draw water toward them through osmosis (used to reduce brain swelling or as a laxative).
• Radioactivity: Iodine-131 and other radioisotopes emit radiation to destroy overactive thyroid tissue.
• Neutralization (Chemical): Antacids are simple chemical bases that react with and neutralize gastric HCl (stomach acid).
• Oxidizing property: Potassium permanganate kills microbes by chemically oxidizing them.
• Chelation: Chelating agents like EDTA and dimercaprol act as chemical claws, grabbing onto and neutralizing heavy metals (like lead or mercury) during poisoning.
• Placebo: Psychological effect with no active pharmacological mechanism.
• Counterfeit mechanism: Sulfa drugs structurally mimic PABA to trick bacteria into using them, shutting down the bacteria's ability to make DNA.
• Protoplasmic poisons: General antiseptics that indiscriminately destroy cell proteins.

B. Majority of Drugs: Target Biomolecules

The vast majority of modern medicines interact with specific Target Biomolecules—which are almost exclusively Proteins. There are four major types of protein targets:

1. Enzymes
2. Ion Channels
3. Transporters
4. Receptors

---

The Four Major Drug Targets

---

Target 1: Enzymes

Almost all biological reactions are carried out under the catalytic influence of enzymes. Therefore, enzymes are a major, highly effective drug target. Drugs can either increase or decrease the rate of enzymatically mediated reactions.

• Enzyme Stimulation: This is relatively rare for drugs. It is more commonly achieved by endogenous (natural) substrates. Examples include Pyridoxine (Vitamin B6) acting as a necessary cofactor to stimulate decarboxylase activity, or Adrenaline stimulating hepatic glycogen phosphorylase (which causes hyperglycemia by releasing sugar from the liver).
• Enzyme Inhibition: This is a very common mode of drug action. Drugs actively block an enzyme from doing its normal job. This inhibition can be competitive (fighting for the same active site as the normal substrate) or non-competitive (binding elsewhere and changing the enzyme's shape).

Key Examples of Enzyme Inhibitors

Other Forms of Inhibition:

• Nonequilibrium (Irreversible): Organophosphorous compounds and deadly Nerve gases permanently bind to and destroy Cholinesterase.
• Non-competitive: Acetazolamide (inhibits carbonic anhydrase), Omeprazole (inhibits the H+/K+ ATPase proton pump in the stomach), and Aspirin (irreversibly inhibits cyclooxygenase).

Target 2: Ion Channels

Proteins take part in transmembrane signaling and regulate the ionic composition of cells. Drugs target these microscopic tunnels to either force them open or block them shut.

• Direct action on channels (Voltage-Sensitive): The drug directly plugs or alters the channel.
  • Local anaesthetics and Class I antiarrhythmics directly act on and depress Na+ (Sodium) channels to stop nerve/heart impulses.
  • Nifedipine directly blocks L-type voltage-sensitive Ca2+ (Calcium) channels to relax blood vessels.
  • Ethosuximide specifically inhibits T-type Ca2+ channels in thalamic neurones to prevent absence seizures in epilepsy.
• Ligand-gated channels: Channels that open only when a specific chemical binds to them (e.g., Nicotinic receptors).
• G-protein operated channels: Channels that are forced open by a remote G-protein complex (e.g., Cardiac β1 adrenergic receptor activated Ca2+ channel).

Target 3: Transporters

Several vital substrates are translocated across cell membranes by binding to specific transporters (carriers). These include Solute Carrier Proteins (SLC) and ATP binding cassettes (ABC). They pump metabolites/ions either in the direction of the concentration gradient or actively against it using metabolic energy.

Drugs interact with these transport systems, usually to block them:

• Probenecid: Blocks the Organic Anion Transporter (OAT), slowing the excretion of penicillin and promoting the excretion of uric acid.
• Furosemide: A powerful diuretic that blocks the Na+/K+/2Cl- cotransport system in the kidney.
• Fluoxetine (Prozac): Acts on the brain to inhibit the neuronal reuptake of Serotonin (5-HT) by blocking the Serotonin Transporter (SERT), leaving more "happy chemical" in the brain.

Target 4: Receptors

Drugs usually do not bind directly with plain enzymes, channels, or structural proteins. Instead, they act through specific master control macromolecules called RECEPTORS.

---

The Vocabulary of Receptors

To understand pharmacodynamics, one must master these exact terms regarding how drugs bind (Affinity) and what they do once bound (Intrinsic Activity/IA):

• Ligand: Simply any molecule which attaches selectively to a particular receptor. A ligand has binding ability (affinity) but doesn't necessarily cause an action.
• Affinity: The fundamental ability of a substrate or drug to latch onto and bind with a receptor.
• Intrinsic Activity (IA) or Efficacy (E): The capacity of the drug, once bound, to induce a functional change in the receptor and trigger a biological response.

Based on these two properties, drugs are classified into four main categories:

Models of Receptor Interaction

• Lock and Key Mechanism: The older theory. The drug (key) must exactly fit the rigid, pre-shaped receptor (lock) to cause a response.
• Induced Fit: The modern theory. The drug binds to the receptor, causing the receptor to dynamically alter its shape (conformational change) wrapping around the drug to create a "Perfect Fit!" and trigger the effect.

---

The Five Major Families of Receptors

---

1. Ion-Channel Receptors (Ionotropic)

These are cell surface receptors, also called ligand-gated ion channels. They physically enclose an ion-selective tunnel (for Na+, K+, Ca2+, or Cl-) within their structure.

• Mechanism: When the agonist ligand (often a fast neurotransmitter like Acetylcholine) binds to the receptor site, the channel instantaneously pops open. Ions flood in or out, causing rapid depolarization or hyperpolarization of the cell.
• Speed: This yields the fastest intracellular response in the human body, occurring in mere microseconds (µs). (This mechanism earned Roderick MacKinnon the 2003 Nobel Prize in Chemistry).
• Examples: Nicotinic Cholinergic receptors, GABA_A and Glycine (which are inhibitory amino acids allowing Cl- in), Excitatory amino-acid receptors like Glutamate (Kainate, NMDA, AMPA types), and 5HT3 (Serotonin) receptors.

2. G-Protein Coupled Receptors (Metabotropic/GPCRs)

The largest family of receptors. They are membrane-bound receptors that consist of a single protein chain threading back and forth through the cell membrane 7 times (7-transmembrane α-helices). They do not have a channel themselves; instead, they are bound to a separate effector system through intermediary G-proteins.

The G-Protein: These are "heterotrimeric" molecules, meaning they have 3 different subunits: Alpha (α), Beta (β), and Gamma (γ). In a resting state, GDP binds the α subunit. When an agonist hits the receptor, GTP replaces GDP, the α subunit breaks off, and it goes to activate cellular machinery. Based on the α-subunit, GPCRs are classified into main varieties:

• Gs (Stimulatory): Activates Adenylyl cyclase, opens Ca2+ channels.
• Gi (Inhibitory): Inhibits Adenylyl cyclase, opens K+ channels.
• Gq: Activates Phospholipase C.
• Go: Inhibits Ca2+ channels.

The Three Major GPCR Effector Pathways

1. Adenylyl Cyclase (cAMP) system: Mediated by Gs. Activation of Adenylyl Cyclase (AC) converts ATP into the second messenger cAMP. cAMP activates Protein Kinase A (PKA). PKA then phosphorylates enzymes to alter their function.
   • Main Results: Increased heart contractility, relaxation of smooth muscles, lipolysis (fat breakdown), glycogenolysis (glycogen breakdown to glucose), inhibition of secretions, and opening of Cyclic Nucleotide Gated (CNG) channels in the heart, brain, and kidney. (Gi produces the exact opposite effects).
2. Phospholipase-C (IP3-DAG) pathway: Mediated by Gq. Activation of PLc hydrolyses the membrane lipid PIP2 into two second messengers: IP3 and DAG. IP3 mobilizes massive amounts of intracellular Ca2+. DAG enhances Protein Kinase C (PKc) activation by the calcium.
   • Main Results: Powerful muscle contraction, cellular secretion/transmitter release, neuronal excitability, eicosanoid synthesis, and cell proliferation.
3. Ion channel regulation: Activated G-proteins can simply walk over to and physically open/close ionic channels (Ca2+, K+, Na+) without the intervention of any second messengers like cAMP or IP3, bringing about direct depolarization.

3. Transmembrane Enzyme-Linked Receptors

Utilized primarily by large peptide hormones (like Insulin). They are made up of a large extracellular ligand-binding domain connected through a single transmembrane helical peptide chain to an intracellular subunit that has direct enzymatic property.

• Intrinsic enzyme receptors: The intracellular domain itself is a protein kinase or guanyl cyclase. Upon binding, the receptors pair up (dimerize) and phosphorylate themselves. Examples: Insulin receptors, Epidermal Growth Factor (EGF), Nerve Growth Factor (NGF).
• JAK-STAT Kinase binding receptors: These have no intrinsic catalytic domain. Instead, when the agonist binds, it induces dimerization which attracts a free-floating cytosolic tyrosine kinase protein (JAK) to bind to the receptor, which then activates STAT proteins to go to the nucleus. Examples: Cytokines, Growth hormone, Prolactin, Interferons.

4. Receptors Regulating Gene Expression (Nuclear/Transcription Factors)

Unlike all others, these receptors are intracellular (floating in the cytoplasm or resting in the nucleus) soluble proteins. Because they are inside, the drug MUST be highly lipid-soluble to penetrate the cell membrane first.

• Mechanism: The lipid-soluble drug enters the cell and binds to the receptor. The complex sheds inhibitory proteins (like heat shock proteins hsp-90), forms a dimer, and moves directly to the nucleus. There, it acts on DNA (Gene Response Elements - GRE) to bind co-activator/co-repressor proteins, altering the transcription of mRNA and synthesizing new proteins.
• Speed: Because it requires making brand new proteins from scratch, this is the slowest mechanism, taking hours to days to show effects.
• Examples: ALL steroidal hormones (Glucocorticoids, mineralocorticoids, androgens, estrogens, progesterone), Thyroxine, Vitamin D, and Vitamin A function in this manner.

5. Enzymes as Receptors

Sometimes the enzyme itself acts as the definitive receptor for the drug's primary action. Examples include ACE (Angiotensin Converting Enzyme), AChE (Acetylcholinesterase), and DHFR (Dihydrofolate Reductase).

---

Functions and Regulation of Receptors

Primary Functions of Receptors:

• To selectively propagate signals from outside the cell to the inside.
• To amplify the signal (one drug molecule can trigger a cascade resulting in thousands of cAMP molecules).
• To integrate various extracellular and intracellular regulatory signals.
• To adapt to long term changes to maintain bodily homeostasis.

Receptor Regulation (Adapting to Drugs)

The body constantly attempts to maintain a baseline. If a drug overstimulates or completely blocks receptors for too long, the body physically alters the receptors. This is known as Receptor Regulation.

Mechanisms Resulting in Decreased (↓) Response

• Tolerance: A gradual reduction in responsiveness as a consequence of continued, long-term drug administration. The body gets used to the drug, requiring higher doses for the same effect.
• Tachyphylaxis: A very rapid, acute reduction in responsiveness following drug administration (often within minutes or hours). Example: Nitroglycerin patches must be removed at night to prevent the body from instantly adapting to them.
• Down Regulation: A physical decrease in the total number of receptors on the cell surface. The cell literally swallows its own receptors (receptor internalization and endocytosis) to hide them from the drug. Example: Chronic use of Beta-2 agonists in asthma leads to down-regulation, making the inhaler less effective over time.
• Desensitization: The receptor is still there, but it becomes "numb." After reaching an initial high response, the effect diminishes over seconds or minutes even in the continued presence of the agonist. This is usually easily reversible once the drug is removed.

Mechanisms Resulting in Increased (↑) Response

• Up Regulation: A physical increase in the number of receptors. This occurs after prolonged occupation of receptors by an antagonist (blocker). Starved of normal stimulation, the cell builds and pushes more receptors to the surface (externalization). If the antagonist is suddenly withdrawn, the elevated number of naked receptors gets hit by normal physiological chemicals, producing a massively exaggerated, potentially fatal response.
• Supersensitivity: An exaggerated response following chronic reduction in normal receptor stimulation.

Spare Receptors and Partial Agonists

A full agonist is so powerful that it does not need to bind to every single receptor to achieve a 100% full response. The extra, unbound receptors are known as Spare Receptors. Conversely, a Partial Agonist has such low intrinsic activity that even if it successfully binds to 100% of the available receptors, it will only ever produce a weak, sub-maximal response.

---

Diseases Resulting from Receptor Malfunction

Sometimes the body's immune system mistakenly produces antibodies that attack its own receptors, leading to severe autoimmune diseases:

• Myasthenia Gravis: Antibodies attack and destroy Nicotinic cholinergic receptors on muscles, leading to severe muscle weakness.
• Insulin-Resistant Diabetes Mellitus: Antibodies attack or block Insulin receptors, making cells deaf to the presence of insulin.
• Grave's Disease: Antibodies bind to the TSH (Thyroid Stimulating Hormone) receptor and act as an agonist, permanently activating it, causing severe hyperthyroidism.
• Atropic Thyroiditis: Antibodies bind to the TSH receptor and act as an antagonist, blocking it, causing hypothyroidism and shrinking of the gland.